EPHA2 and prostate cancer: Preclinical studies indicated that treatment with MEDI-547 induced EphA2 degradation and internalization, decreased proliferation, increased apoptosis, and displayed antiangiogenic effects in endometrial and prostate cancer cells and mouse and rat orthotopic models [91,94].